New Sartorius Stedim BioOutsource microsite goes live
Cellca’s cell line and upstream process development services now integrated.
Sartorius Stedim Biotech's (SSB's) subsidiary BioOutsource has launched an updated website to spotlight Sartorius Stedim Cellca’s cell line and upstream process development services for the biopharmaceutical industry. The new microsite features insights into the technology and development services of Cellca most recently acquired by SSB. The availability of both subsidiaries’ unique range of integrated services will support biopharma companies to rapidly and cost-effectively develop their biologics and biosimilars.
The new microsite divides into four easy-to-navigate sections that explain Cellca’s unique CHO Expression Platform which comprises of Expression Vector, Host Cell Line, CHO Media System and Upstream Process Design. This structure gives a simple overview of the technical details and time-saving benefits of this robust, scalable expression platform for individual applications.
Cellca’s cell line and upstream process development services complement BioOutsource’s broad range of bioanalytical and biosafety testing, as well as pre-qualified biosimilar assays. As a result, scientists and potential customers can source all their needs for developing biologics and biosimilars from one trusted supplier. Additionally, as both Cellca and BioOutsource have been part of Sartorius Stedim Biotech since 2015, biopharma firms that need to commercialize their biologics will not only benefit from this niche expertise, but can also access SSB’s extensive global upstream process development capabilities to accelerate the development timeline of their biologics and biosimilars.
Gerry MacKay, Managing Director of Sartorius Stedim BioOutsource, commented: “We’re pleased to be launching our new microsite because it signals the availability of our unique integrated services. Developers of biologics and biosimilars can now go to our site to find out how to access a fully integrated pathway from cell line development and data characterization through to upstream process development. They can also discover how these services will support them to comply with regulatory standards for timely, cost-effective development of their biosimilars.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance